Equities

Clinica Baviera SA

Clinica Baviera SA

Actions
  • Price (EUR)28.10
  • Today's Change-0.40 / -1.40%
  • Shares traded7.47k
  • 1 Year change+51.48%
  • Beta0.5499
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clinica Baviera SA is a Spain-based company engaged in the healthcare sector. The Company focuses on providing services within the field of ophthalmic medicine. The Company is specialized in the diagnosis and treatment of eye disorders, including myopia, hyperopia, astigmatism, cataracts, glaucoma, vitreous-retina and strabismus, among others. The Company operates a network of clinics located in various European countries, such as Spain, Germany, Austria and Italy. In addition, the Company is a parent of the Baviera Group, a group that comprises a number of controlled entities, including Clinica Baviera Italia Srl, Clinica Baviera Mallorca SL, Care Vision Germany GmbH and Castellana de Intermediacion Sanitaria SL, among others. The main shareholder of the Company is Aier Eye International (Europe) Slu.

  • Revenue in EUR (TTM)224.92m
  • Net income in EUR36.42m
  • Incorporated1992
  • Employees1.35k
More ▼

Institutional shareholders

4.10%Per cent of shares held by top holders
HolderShares% Held
Santander Asset Management SA SGIICas of 31 Dec 2023283.03k1.74%
Gay-Lussac Gestion SAas of 31 Dec 2022260.00k1.59%
Independance Et Expansion AM SARLas of 30 Jun 202385.72k0.53%
Santander Private Banking Gestion SA SGIICas of 31 Dec 202332.32k0.20%
Apicil Asset Management SAas of 29 Dec 20237.39k0.05%
Acadian Asset Management LLCas of 30 Sep 2023130.000.00%
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.